You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 13, 2024

~ Buy the ORBACTIV (oritavancin diphosphate) Drug Profile, 2024 PDF Report in the Report Store ~

ORBACTIV Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Orbactiv, and what generic alternatives are available?

Orbactiv is a drug marketed by Melinta Therap and is included in one NDA. There are three patents protecting this drug.

This drug has thirty-nine patent family members in seventeen countries.

The generic ingredient in ORBACTIV is oritavancin diphosphate. One supplier is listed for this compound. Additional details are available on the oritavancin diphosphate profile page.

DrugPatentWatch® Generic Entry Outlook for Orbactiv

Orbactiv was eligible for patent challenges on August 6, 2018.

Indicators of Generic Entry

< Available with Subscription >

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ORBACTIV?
  • What are the global sales for ORBACTIV?
  • What is Average Wholesale Price for ORBACTIV?
Summary for ORBACTIV
International Patents:39
US Patents:3
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 27
Clinical Trials: 7
Patent Applications: 25
Drug Prices: Drug price information for ORBACTIV
What excipients (inactive ingredients) are in ORBACTIV?ORBACTIV excipients list
DailyMed Link:ORBACTIV at DailyMed
Drug patent expirations by year for ORBACTIV
Drug Prices for ORBACTIV

See drug prices for ORBACTIV

Recent Clinical Trials for ORBACTIV

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Melinta Therapeutics, Inc.Phase 2
Melinta Therapeutics, Inc.Phase 1
The Medicines CompanyPhase 4

See all ORBACTIV clinical trials

US Patents and Regulatory Information for ORBACTIV

ORBACTIV is protected by three US patents and two FDA Regulatory Exclusivities.

Patents protecting ORBACTIV

Methods of treatment using single doses of oritavancin
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS USING A SINGLE DOSE

High purity oritavancin and method of producing same
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Methods of treating bacterial infections using oritavancin
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS

FDA Regulatory Exclusivity protecting ORBACTIV

NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷  Sign Up

GENERATING ANTIBIOTIC INCENTIVES NOW
Exclusivity Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Melinta Therap ORBACTIV oritavancin diphosphate POWDER;INTRAVENOUS 206334-001 Aug 6, 2014 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Melinta Therap ORBACTIV oritavancin diphosphate POWDER;INTRAVENOUS 206334-001 Aug 6, 2014 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Melinta Therap ORBACTIV oritavancin diphosphate POWDER;INTRAVENOUS 206334-001 Aug 6, 2014 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ORBACTIV

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Melinta Therap ORBACTIV oritavancin diphosphate POWDER;INTRAVENOUS 206334-001 Aug 6, 2014 ⤷  Sign Up ⤷  Sign Up
Melinta Therap ORBACTIV oritavancin diphosphate POWDER;INTRAVENOUS 206334-001 Aug 6, 2014 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for ORBACTIV

See the table below for patents covering ORBACTIV around the world.

Country Patent Number Title Estimated Expiration
Eurasian Patent Organization 201100413 СПОСОБ ЛЕЧЕНИЯ БАКТЕРИАЛЬНОЙ ИНФЕКЦИИ ⤷  Sign Up
Argentina 010621 METODO PARA LA ALQUILACION EN FORMA REDUCTORA DE UN ANTIBIOTICO GLICOPEPTIDO, COMPLEJO DE COBRE CON UN ANTIBIOTICO GLICOPEPTIDO ALQUILADO EN FORMAR REDUCTORA Y METODO PARA PREPARAR DICHO ANTIBIOTICO GLICOPEPTIDO ALQUILADO ⤷  Sign Up
Austria 286910 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for ORBACTIV

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2337575 41/2016 Austria ⤷  Sign Up PRODUCT NAME: ORITAVANCIN UND DESSEN PHARMAZEUTISCHE SALZE; REGISTRATION NO/DATE: EU/1/15/989 (MITTEILUNG) 20150323
2337575 122016000075 Germany ⤷  Sign Up PRODUCT NAME: ORITAVANCIN ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/989 20150319
2337575 2016019 Norway ⤷  Sign Up PRODUCT NAME: ORITAVANCIN OG FARMASOEYTISK; REG. NO/DATE: EU/1/15/989 20150415
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.